2020 Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes

Das, Sandeep R.; Everett, Brendan M.; Birtcher, Kim K.; Brown, Jenifer M.; Januzzi, James L.; Kalyani, Rita R.; Kosiborod, Mikhail; Magwire, Melissa; Morris, Pamela B.; Neumiller, Joshua J.; Sperling, Laurence S.

doi:10.1016/j.jacc.2020.05.037

Cited by 466Diabetes Treatment and ManagementDiabetes, Cardiovascular Risks, and LipoproteinsAntiplatelet Therapy and Cardiovascular Diseases

2020 Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes

Open access

Das, Sandeep R., Everett, Brendan M., Birtcher, Kim K., Brown, Jenifer M., Januzzi, James L., Kalyani, Rita R., Kosiborod, Mikhail, Magwire, Melissa +3 more·2020·Journal of the American College of Cardiology

DOI 10.1016/j.jacc.2020.05.037PMC PMC7545583

Open this paper in CoChat — free account

Abstract

Ty J. Gluckman, MD, FACC, Chair Niti R. Aggarwal, MD, FACC Nicole M. Bhave, MD, FACC Gregory J. Dehmer, MD, MACC Olivia N. Gilbert, MD, MSc, FACC Chayakrit Krittanawong, MD Dharam J. Kumbhani, MD, SM, FACC Andrea L. Price, CPHQ, RCIS, AACC Javier A. Sala-Mercado, MD, PhD David E.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1016/j.jacc.2020.05.037

Cites

111 of 111 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Lifestyle intervention can reduce side effects in patients taking GLP-1 receptor agonists.
“Lifestyle intervention can also reduce side effects in patients taking GLP-1 receptor agonists including recommending smaller (and if needed, more frequent) meals that are lower in fat [14,86].”
From Lifestyle Medicine for Obesity in the Era of Highly Effective Anti-Obesity Treatment (2025) · cites this paper as [86]
In “What to Monitor When Prescribing a GLP-1RA,” the consensus says eating smaller portions and following a low-fat diet can help minimize nausea and vomiting. It does not recommend eating more frequently, even if needed. (LLM, conf=0.85)
Experimental — accuracy not yet measured
The anti-inflammatory effects of GLP-1 RAs and SGLT2i are not fully elucidated.
“This gap in knowledge is especially pronounced in the case of glucagon-like peptide-1 receptor agonist (GLP-1 RA) and sodium-glucose cotransporter 2 inhibitor (SGLT2i), which have shown promise in reducing cardiovascular and renal risks but whose anti-inflammatory effects are not fully elucidated.23”
From The effect of <scp>GLP</scp> ‐1 receptor agonists on circulating inflammatory markers in type 2 diabetes patients: A systematic review and meta‐analysis (2025) · cites this paper as [23]
The Introduction says the mechanisms behind cardiovascular and renal benefits remain uncertain, and the GLP-1RA Mechanisms of Action section identifies anti-inflammatory effects. The SGLT2 Inhibitors Mechanism of Action section also says its mechanisms of benefit are not fully elucidated. However, the paper does not specifically say that the anti-inflammatory effects of both drug classes are not fully elucidated; it does not identify anti-inflammatory effects for SGLT2 inhibitors. (LLM, conf=0.84)
Experimental — accuracy not yet measured
The American Diabetes Association, the American College of Cardiology, and the European Society of Cardiology recommend that patients with type 2 diabetes with established or at risk of atherosclerotic cardiovascular disease, chronic kidney disease, or heart failure be prescribed an SGLT2i or GLP-1 RA, irrespective of glycemic control or metformin use.
“These findings prompted the American Diabetes Association,2 the American College of Cardiology,3 and the European Society of Cardiology4 to recommend that patients with type 2 diabetes with established or at risk of atherosclerotic cardiovascular disease, chronic kidney disease, or heart failure, be prescribed an SGLT2i or GLP-1 RA, irrespective of glycemic control or metformin use.”
From Race and ethnicity and pharmacy dispensing of SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetes (2024) · cites this paper as [3]
In general, comorbidities were independently associated with pharmacy dispensing of these drugs, which aligns with national guidelines.
“In general, comorbidities were independently associated with pharmacy dispensing of these drugs, which aligns with national guidelines.2, 3, 4”
From Race and ethnicity and pharmacy dispensing of SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetes (2024) · cites this paper as [3]
In an analysis of repeat hospitalization after first-ever lifetime stroke, diabetes was noted to increase the risk of repeat hospitalization for all causes.
“In an analysis of repeat hospitalization after first-ever lifetime stroke, DM was noted to increase the risk of repeat hospitalization for all causes.658”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [658]
The Introduction discusses elevated cardiovascular risk in people with type 2 diabetes, while the SGLT2 Inhibitors section discusses hospitalization for heart failure. Neither reports an analysis of all-cause repeat hospitalization after a first-ever stroke. Searches for first-ever stroke readmission and recurrent hospitalization found no passage addressing that claim. (LLM, conf=0.76)
Experimental — accuracy not yet measured

After an initial cerebrovascular accident, whether transient ischemic attack or stroke, the risk of recurrence and mortality increases.
“After the initial cerebrovascular accident (CVA), whether transient ischemic attack or stroke, the risk of recurrence and mortality increases.”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [658]
The Definitions section lists prior stroke as a form of atherosclerotic cardiovascular disease, and the Description and Rationale sections discuss stroke and mortality as trial outcomes. No passage found addresses whether an initial stroke or transient ischemic attack increases the risk of recurrence and mortality; searches included those terms and recurrent stroke. Page numbers were unavailable in our copy. (LLM, conf=0.75)
Experimental — accuracy not yet measured
Updated American Diabetes Association guidelines and the American College of Cardiology expert consensus statement now recommend SGLT2 inhibitor use for diabetic patients who have or are at high risk for cardiovascular disease, CKD, or heart failure regardless of current glycemic control.
“Given the demonstrated benefits of SGLT2 inhibitors, the updated American Diabetes Association guidelines10 and the American College of Cardiology expert consensus statement11 now recommend their use for diabetic patients who have or are at high risk for cardiovascular disease, CKD, or heart failure regardless of current glycemic control.”
From Association of race/ethnicity, gender, and socioeconomic status with sodium-glucose cotransporter 2 inhibitor use among patients with diabetes in the US (2021) · cites this paper as [11]
Guidelines from the ADA, ACC, and ESC endorse the use of GLP1-RA in treatment algorithms for ASCVD prevention for patients with T2D at elevated cardiovascular risk.
“This has led to guidelines from the ADA [45], the American College of Cardiology (ACC) [46], and the European Society of Cardiology (ESC)[47] endorsing the use of GLP1-RA in treatment algorithms for the purposes of ASCVD prevention for patients with T2D at elevated cardiovascular risk.”
From Glucagon-like peptide-1 receptor agonists in diabetic kidney disease: a review of their kidney and heart protection (2023) · cites this paper as [46]
Multiple diabetes, cardiovascular, and kidney organizations endorse the use of GLP1-RA in their guideline recommendations.
“Despite multiple diabetes, cardiovascular, and kidney organizations endorsing the use of GLP1-RA in their guideline recommendations [45], [46], [47]”
From Glucagon-like peptide-1 receptor agonists in diabetic kidney disease: a review of their kidney and heart protection (2023) · cites this paper as [46]
GLP-1 receptor agonists reduce major adverse cardiovascular events in patients with type 2 diabetes in both primary and secondary prevention settings.
“GLP-1RAs have been shown to reduce the incidence of major adverse CV events in patients with T2D, in the settings of both primary and secondary prevention.[18][19][20]”
From Management of type 2 diabetes, obesity, or nonalcoholic steatohepatitis with high‐dose GLP‐1 receptor agonists and GLP‐1 receptor‐based co‐agonists (2024) · cites this paper as [20]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)
(1998) · The Lancet · doi:10.1016/s0140-6736(98)07019-6 · Cited by 20,023 · see citing works
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012512 · Cited by 19,011 · cited 1× · see citing works
“A Focus on Comprehensive CV Risk Reduction in T2D Although the primary focus of patients, clinicians, and healthcare systems should be the prevention of T2D (25), a significant proportion of patients cared for by CV clinicians have known T2D, undiagnosed diabetes, or prediabetes (26).”
Background
2013 ACCF/AHA Guideline for the Management of Heart Failure
Yancy, C. W., Jessup, M., Bozkurt, B., Butler, J., Casey, D. E., Drazner, M. H., Fonarow, G. C., Geraci, S. A., Horwich, T., Januzzi, J. L., et al. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.05.019 · Cited by 12,536 · see citing works
Self-citation
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315 · cited 2× · see citing works
“SGLT2 Inhibitors and ASCVD Events—The EMPA-REG OUTCOME (Empagliflozin CV Outcome Event Trial in T2D Patients) trial (12) showed a 14% relative risk reduction in the primary endpoint of 3-point MACE (hazard ratio [HR]: 0.”
Background
Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group.
Turner, R. C., Fox, C., Matthews, McElroy, H. H., Cull, C. A., Holman, R. R., Neil, P., Hadden, D. R., Wright, D., Manley, E., et al. (1998) · The Lancet · Cited by 8,419 · see citing works
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Neal, B., Perkovic, V., Mahaffey, K. W., de Zeeuw, D., Fulcher, G., Erondu, N., Shaw, W., Law, G., Desai, M., & Matthews, D. R. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1611925 · Cited by 7,830 · see citing works
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629 · cited 5× · see citing works
“Compared with placebo, use of liraglutide produced a 20% reduction in the occurrence of confirmed hypoglycemia and a 31% reduction in severe hypoglycemia (14).”
BackgroundInfluential
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802987 · Cited by 7,397 · see citing works
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
McMurray, J. J. V., Solomon, S. D., Inzucchi, S. E., Køber, L., Kosiborod, M. N., Martinez, F. A., Ponikowski, P., Sabatine, M. S., Anand, I. S., Bělohlávek, J., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1911303 · Cited by 7,140 · see citing works
Self-citation
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900 · cited 6× · see citing works
“A metaanalysis of the data from ELIXA, EXSCEL, LEADER, and SUSTAIN-6 reported a 12% (HR: 0.88; 95% CI: 0.84 to 0.94) relative reduction in the risk of MACE across those trials.”
BackgroundMethodInfluential
2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults
Whelton, P. K., Carey, R. M., Aronow, W. S., Casey, D. E., Collins, K. J., Dennison Himmelfarb, C., DePalma, S. M., Gidding, S., Jamerson, K. A., Jones, D. W., et al. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.11.006 · Cited by 6,616 · see citing works
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
Wiviott, S. D., Raz, I., Bonaca, M. P., Mosenzon, O., Kato, E. T., Cahn, A., Silverman, M. G., Zelniker, T. A., Kuder, J. F., Murphy, S. A., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1812389 · Cited by 6,382 · see citing works
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
Perkovic, V., Jardine, M. J., Neal, B., Bompoint, S., Heerspink, H. J. L., Charytan, D. M., Edwards, R., Agarwal, R., Bakris, G., Bull, S., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1811744 · Cited by 6,189 · cited 35× · see citing works
“Benefits and adverse effects in the group with the lowest eGFR were consistent with those in the remainder of the cohort (19).”
BackgroundMethodResultInfluential
2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines
Grundy, S. M., Stone, N. J., Bailey, A. L., Beam, C., Birtcher, K. K., Blumenthal, R. S., Braun, L. T., de Ferranti, S., Faiella-Tommasino, J., Forman, D. E., et al. (2019) · Circulation · doi:10.1161/cir.0000000000000625 · Cited by 6,185 · see citing works
Self-citation
2019 ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD
Cosentino, F., Grant, P. J., Aboyans, V., Bailey, C. J., Ceriello, A., Delgado, V., Federici, M., Filippatos, G., Grobbee, D. E., Hansen, T. B., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz486 · Cited by 4,763 · see citing works
Glucose control and vascular complications in veterans with type 2 diabetes
Duckworth, W., Abraira, C., Moritz, T., Reda, D., Emanuele, N., Reaven, P. D., Zieve, F. J., Marks, J., Davis, S. N., Hayward, R., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808431 · Cited by 4,762 · see citing works
2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.
Arnett, D. K., Blumenthal, R. S., Albert, M. A., Buroker, A. B., Goldberger, Z. D., Hahn, E. J., Himmelfarb, C. D., Khera, A., Lloyd-Jones, D., McEvoy, J. W., et al. (2019) · Circulation · doi:10.1161/cir.0000000000000678 · Cited by 4,536 · see citing works
Untitled work
(2019) · doi:10.1161/cir.0000000000000677 · Cited by 4,501 · see citing works
Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes
Gæde, P., Vedel, P., Larsen, N., Jensen, G. V. H., Parving, H.-H., & Pedersen, O. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021778 · Cited by 4,378 · see citing works
Economic Costs of Diabetes in the U.S. in 2002
American Diabetes Association (2003) · Diabetes Care · doi:10.2337/diacare.26.3.917 · Cited by 4,147 · see citing works
Dietary Advanced Glycation End Products and Their Potential Role in Cardiometabolic Disease in Children
Gupta, A., & Uribarri, J. (2016) · Hormone Research in Paediatrics · doi:10.1159/000444053 · Cited by 4,019 · see citing works
Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes
Wanner, C., Inzucchi, S. E., Lachin, J. M., Fitchett, D., von Eynatten, M., Mattheus, M., Johansen, O. E., Woerle, H. J., Broedl, U. C., & Zinman, B. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1515920 · Cited by 3,655 · see citing works
Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the american diabetes association (ADA) and the european association for the study of diabetes (EASD)
Davies, M. J., D’Alessio, D. A., Fradkin, J., Kernan, W. N., Mathieu, C., Mingrone, G., Rossing, P., Tsapas, A., Wexler, D. J., & Buse, J. B. (2018) · Diabetes Care · doi:10.2337/dci18-0033 · Cited by 3,518 · see citing works
2013 ACCF/AHA Guideline for the Management of Heart Failure: Executive Summary: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines
Yancy, C. W., Jessup, M., Bozkurt, B., Butler, J., Casey, D. E., Drazner, M. H., Fonarow, G. C., Geraci, S. A., Horwich, T., Januzzi, J. L., et al. (2013) · Circulation · doi:10.1161/cir.0b013e31829e8807 · Cited by 3,304 · see citing works
Self-citation
Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial
Gerstein, H. C., Colhoun, H. M., Dagenais, G. R., Diaz, R., Lakshmanan, M., Pais, P., Probstfield, J., Riesmeyer, J. S., Riddle, M. C., Rydén, L., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31149-3 · Cited by 3,163 · see citing works
Self-citation
SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials
Zelniker, T. A., Wiviott, S. D., Raz, I., Im, K., Goodrich, E. L., Bonaca, M. P., Mosenzon, O., Kato, E. T., Cahn, A., Furtado, R. H. M., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(18)32590-x · Cited by 2,845 · see citing works
2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol
Grundy, S. M., Stone, N. J., Bailey, A. L., Beam, C., Birtcher, K. K., Blumenthal, R. S., Braun, L. T., de Ferranti, S., Faiella-Tommasino, J., Forman, D. E., et al. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.11.003 · Cited by 2,691 · see citing works
Self-citation
Economic Costs of Diabetes in the U.S. in 2017
American Diabetes Association (2018) · Diabetes Care · doi:10.2337/dci18-0007 · Cited by 2,528 · see citing works
2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease: Executive Summary
Fihn, S. D., Gardin, J. M., Abrams, J., Berra, K., Blankenship, J. C., Dallas, A. P., Douglas, P. S., Foody, J. M., Gerber, T. C., Hinderliter, A. L., et al. (2012) · Circulation · doi:10.1161/cir.0b013e3182776f83 · Cited by 2,411 · see citing works
Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome
Pfeffer, M. A., Claggett, B., Diaz, R., Dickstein, K., Gerstein, H. C., Køber, L. V., Lawson, F. C., Ping, L., Wei, X., Lewis, E. F., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1509225 · Cited by 2,409 · see citing works
Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes
Holman, R. R., Bethel, M. A., Mentz, R. J., Thompson, V. P., Lokhnygina, Y., Buse, J. B., Chan, J. C., Choi, J., Gustavson, S. M., Iqbal, N., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1612917 · Cited by 2,162 · see citing works
2013 ACCF/AHA Guideline for the Management of Heart Failure
Yancy, C. W., Jessup, M. L., Bozkurt, B., Butler, J., Casey, D. E., Drazner, M. H., Fonarow, G. C., Geraci, S. A., Horwich, T. B., Januzzi, J. L., et al. (2013) · Circulation · doi:10.1161/cir.0b013e31829e8776 · Cited by 2,129 · see citing works
Self-citation
Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Husain, M., Birkenfeld, A. L., Donsmark, M., Dungan, K., Eliaschewitz, F. G., Franco, D. R., Jeppesen, O. K., Lingvay, I., Mosenzon, O., Pedersen, S. D., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1901118 · Cited by 1,997 · see citing works
2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease
Arnett, D. K., Blumenthal, R. S., Albert, M. A., Buroker, A. B., Goldberger, Z. D., Hahn, E. J., Himmelfarb, C. D., Khera, A., Lloyd-Jones, D., McEvoy, J. W., et al. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.03.010 · Cited by 1,896 · see citing works
Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): A double-blind, randomised placebo-controlled trial
Hernandez, A. F., Green, J. B., Janmohamed, S., D'Agostino, R. B., Granger, C. B., Jones, N. P., Leiter, L. A., Rosenberg, A. E., Sigmon, K. N., Somerville, M. C., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)32261-x · Cited by 1,829 · see citing works
Self-citation
Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials
Kristensen, S. L., Rørth, R., Jhund, P. S., Docherty, K. F., Sattar, N., Preiss, D., Køber, L., Petrie, M. C., & McMurray, J. J. V. (2019) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(19)30249-9 · Cited by 1,663 · cited 5× · see citing works
“The potential for clinically relevant heterogeneity within the class exists, leaving dulaglutide, liraglutide, and injectable semaglutide the currently preferred agents (albiglutide is no longer available in the United States) (80).”
BackgroundResultInfluential
2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease
Fihn, S. D., Gardin, J. M., Abrams, J., Berra, K., Blankenship, J. C., Dallas, A. P., Douglas, P. S., Foody, J. M., Gerber, T. C., Hinderliter, A. L., et al. (2012) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.07.013 · Cited by 1,560 · see citing works
Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
Davies, M. J., D’Alessio, D. A., Fradkin, J., Kernan, W. N., Mathieu, C., Mingrone, G., Rossing, P., Tsapas, A., Wexler, D. J., & Buse, J. B. (2018) · Diabetologia · doi:10.1007/s00125-018-4729-5 · Cited by 1,455 · see citing works
Mortality and cardiovascular disease in type 1 and type 2 diabetes
Rawshani, A., Rawshani, A., Franzén, S., Eliasson, B., Svensson, A.-M., Miftaraj, M., McGuire, D. K., Sattar, N., Rosengren, A., & Gudbjörnsdottir, S. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1608664 · Cited by 1,389 · see citing works
2019 update to: management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
Buse, J. B., Wexler, D. J., Tsapas, A., Rossing, P., Mingrone, G., Mathieu, C., D’Alessio, D. A., & Davies, M. J. (2020) · Diabetes Care · doi:10.2337/dci19-0066 · Cited by 1,192 · see citing works
C-reactive protein, fibrinogen, and cardiovascular disease prediction
The Emerging Risk Factors Collaboration (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1107477 · Cited by 1,150 · see citing works
SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review
Verma, S., & McMurray, J. J. V. (2018) · Diabetologia · doi:10.1007/s00125-018-4670-7 · Cited by 999 · see citing works
Standards of Medical Care in Diabetes—2017 Abridged for Primary Care Providers
American Diabetes Association (2017) · Clinical Diabetes · doi:10.2337/cd16-0067 · Cited by 977 · see citing works
Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME ® trial
Fitchett, D., Zinman, B., Wanner, C., Lachin, J. M., Hantel, S., Salsali, A., Johansen, O. E., Woerle, H. J., Broedl, U. C., & Inzucchi, S. E. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehv728 · Cited by 907 · see citing works
2016 ACC/AHA/HFSA Focused Update on New Pharmacological Therapy for Heart Failure: An Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America
Yancy, C. W., Jessup, M. L., Bozkurt, B., Butler, J., Casey, D. E., Colvin, M. M., Drazner, M. H., Filippatos, G. S., Fonarow, G. C., Givertz, M. M., et al. (2016) · Circulation · doi:10.1161/cir.0000000000000435 · Cited by 899 · see citing works
2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons
Fihn, S. D., Gardin, J. M., Abrams, J., Berra, K., Blankenship, J. C., Dallas, A. P., Douglas, P. S., Foody, J. M., Gerber, T. C., Hinderliter, A. L., et al. (2012) · Circulation · doi:10.1161/cir.0b013e318277d6a0 · Cited by 845 · see citing works
Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus: Systematic Review and Meta-Analysis of Cardiovascular Outcomes Trials
Zelniker, T. A., Wiviott, S. D., Raz, I., Im, K., Goodrich, E. L., Furtado, R. H. M., Bonaca, M. P., Mosenzon, O., Kato, E. T., Cahn, A., et al. (2019) · Circulation · doi:10.1161/circulationaha.118.038868 · Cited by 781 · see citing works
How does empagliflozin reduce cardiovascular mortality? Insights from a mediation analysis of the EMPA-REG OUTCOME Trial
Inzucchi, S. E., Zinman, B., Fitchett, D., Wanner, C., Ferrannini, E., Schumacher, M., Schmoor, C., Ohneberg, K., Johansen, O. E., George, J. T., et al. (2018) · Diabetes Care · doi:10.2337/dc17-1096 · Cited by 740 · see citing works
2014 ACC/AHA Key Data Elements and Definitions for Cardiovascular Endpoint Events in Clinical Trials
Hicks, K. A., Tcheng, J. E., Bozkurt, B., CHAITMAN, B. R., Cutlip, D. E., Farb, A. A., Fonarow, G. C., Jacobs, J. P., Jaff, M. R., Lichtman, J. H., et al. (2014) · Circulation · doi:10.1161/cir.0000000000000156 · Cited by 706 · see citing works
The UK Prospective Diabetes Study (UKPDS): clinical and therapeutic implications for type 2 diabetes
King, P., Peacock, I., & Donnelly, R. (1999) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.1999.00092.x · Cited by 703 · see citing works
Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE–TIMI 58 randomised trial
Mosenzon, O., Wiviott, S. D., Cahn, A., Rozenberg, A., Yanuv, I., Goodrich, E. L., Murphy, S. A., Heerspink, H. J. L., Zelniker, T. A., Dwyer, J. P., et al. (2019) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(19)30180-9 · Cited by 684 · see citing works
Euglycemic diabetic ketoacidosis: a predictable, detectable, and preventable safety concern with SGLT2 inhibitors
Rosenstock, J., & Ferrannini, E. (2015) · Diabetes Care · doi:10.2337/dc15-1380 · Cited by 664 · see citing works
Targeting renal glucose reabsorption to treat hyperglycaemia: the pleiotropic effects of SGLT2 inhibition
Vallon, V., & Thomson, S. C. (2017) · Diabetologia · doi:10.1007/s00125-016-4157-3 · Cited by 635 · see citing works
Standards of Medical Care in Diabetes—2020 Abridged for Primary Care Providers
Riddle, M., & Holl, R. (2019) · Clinical Diabetes · doi:10.2337/cd20-as01 · Cited by 616 · see citing works
2016 ACC/AHA/HFSA Focused Update on New Pharmacological Therapy for Heart Failure: An Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure
Yancy, C. W., Jessup, M. L., Bozkurt, B., Butler, J., Casey, D. E., Colvin, M. M., Drazner, M. H., Filippatos, G. S., Fonarow, G. C., Givertz, M. M., et al. (2016) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2016.05.011 · Cited by 614 · see citing works
2014 ACC/AHA Key Data Elements and Definitions for Cardiovascular Endpoint Events in Clinical Trials
Hicks, K. A., Tcheng, J. E., Bozkurt, B., CHAITMAN, B. R., Cutlip, D. E., Farb, A. A., Fonarow, G. C., Jacobs, J. P., Jaff, M. R., Lichtman, J. H., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.12.018 · Cited by 608 · see citing works
Cardiovascular Actions and Clinical Outcomes With Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors
Nauck, M. A., Meier, J. J., Cavender, M. A., Abd El Aziz, M., & Drucker, D. J. (2017) · Circulation · doi:10.1161/circulationaha.117.028136 · Cited by 582 · see citing works
Canagliflozin for Primary and Secondary Prevention of Cardiovascular Events: Results From the CANVAS Program (Canagliflozin Cardiovascular Assessment Study)
Mahaffey, K. W., Neal, B., Perkovic, V., de Zeeuw, D., Fulcher, G., Erondu, N., Shaw, W., Fabbrini, E., Sun, T., Li, Q., et al. (2018) · Circulation · doi:10.1161/circulationaha.117.032038 · Cited by 498 · see citing works
10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes—2020
American Diabetes Association (2020) · Diabetes Care · doi:10.2337/dc20-s010 · Cited by 487 · see citing works
Randomized, Double-Blind, Placebo-Controlled, Multicentre Pilot Study on the Effects of Empagliflozin on Clinical Outcomes in Patients with Acute Decompensated Heart Failure (EMPA-RESPONSE-AHF)
Damman, K., Beusekamp, J. C., Boorsma, E. M., Swart, H. P., Smilde, T. D. J., Elvan, A., van Eck, J. W. M., Heerspink, H. J. L., & Voors, A. A. (2020) · European Journal of Heart Failure · doi:10.1002/ejhf.1713 · Cited by 460 · see citing works
11. Microvascular Complications and Foot Care: Standards of Medical Care in Diabetes−2020
American Diabetes Association (2020) · Diabetes Care · doi:10.2337/dc20-s011 · Cited by 460 · see citing works
Incretin therapies: highlighting common features and differences in the modes of action of glucagon‐like peptide‐1 receptor agonists and dipeptidyl peptidase‐4 inhibitors
Nauck, M. (2016) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12591 · Cited by 429 · see citing works
Dapagliflozin Effects on Biomarkers, Symptoms, and Functional Status in Patients With Heart Failure With Reduced Ejection Fraction: The DEFINE-HF Trial
Nassif, M. E., Windsor, S. L., Tang, F., Khariton, Y., Husain, M., Inzucchi, S. E., McGuire, D. K., Pitt, B., Scirica, B. M., Austin, B., et al. (2019) · Circulation · doi:10.1161/circulationaha.119.042929 · Cited by 424 · see citing works
Self-citation
Exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy (DURATION-8): a 28 week, multicentre, double-blind, phase 3, randomised controlled trial
Frías, J. P., Guja, C., Hardy, E., Ahmed, A., Dong, F., Öhman, P., & Jabbour, S. A. (2016) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(16)30267-4 · Cited by 399 · see citing works
Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease: an exploratory analysis from the EMPA-REG outcome randomised, placebo-controlled trial
Cherney, D. Z. I., Zinman, B., Inzucchi, S. E., Koitka-Weber, A., Mattheus, M., von Eynatten, M., & Wanner, C. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30182-1 · Cited by 383 · see citing works
2017 Focused Update of the 2016 ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk
Lloyd‐Jones, D. M., Morris, P. B., Ballantyne, C. M., Birtcher, K. K., Daly, D. D., DePalma, S. M., Minissian, M., Orringer, C. E., & Smith, S. C. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.07.745 · Cited by 383 · see citing works
Self-citation
Semaglutide once weekly as add-on to SGLT-2 inhibitor therapy in type 2 diabetes (SUSTAIN 9): a randomised, placebo-controlled trial
Zinman, B., Bhosekar, V., Busch, R., Holst, I., Ludvik, B., Thielke, D., Thrasher, J., Woo, V., & Philis-Tsimikas, A. (2019) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(19)30066-x · Cited by 376 · see citing works
Dapagliflozin and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus and Previous Myocardial Infarction
Furtado, R. H. M., Bonaca, M. P., Raz, I., Zelniker, T. A., Mosenzon, O., Cahn, A., Kuder, J., Murphy, S. A., Bhatt, D. L., Leiter, L. A., et al. (2019) · Circulation · doi:10.1161/circulationaha.119.039996 · Cited by 335 · see citing works
Introduction: Standards of Medical Care in Diabetes—2019
Frías, J. P. (2018) · Diabetes Care · doi:10.2337/dc19-sint01 · Cited by 331 · see citing works
Introduction: Standards of Medical Care in Diabetes—2020
(2020) · Diabetes Care · doi:10.2337/dc20-sint · Cited by 331 · see citing works
Diabetic Ketoacidosis and Related Events in the Canagliflozin Type 2 Diabetes Clinical Program
Erondu, N., Desai, M. G., Ways, K., & Meininger, G. E. (2015) · Diabetes Care · doi:10.2337/dc15-1251 · Cited by 324 · see citing works
2018 ACC Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes and Atherosclerotic Cardiovascular Disease
Das, S. R., Everett, B. M., Birtcher, K. K., Brown, J. M., Cefalu, W. T., Januzzi, J. L., Kalyani, R. R., Kosiborod, M., Magwire, M. L., Morris, P. B., et al. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.09.020 · Cited by 300 · see citing works
Self-citation
Comparative efficacy, safety, and cardiovascular outcomes with once-weekly subcutaneous semaglutide in the treatment of type 2 diabetes: Insights from the SUSTAIN 1–7 trials
Aroda, V. R., Ahmann, A., Cariou, B., Chow, F., Davies, M. J., Jódar, E., Mehta, R., Woo, V., & Lingvay, I. (2019) · Diabetes & Metabolism · doi:10.1016/j.diabet.2018.12.001 · Cited by 296 · see citing works
The CardioMetabolic Health Alliance
Sperling, L. S., Mechanick, J. I., Neeland, I. J., Herrick, C. J., Després, J.-P., Ndumele, C. E., Vijayaraghavan, K., Handelsman, Y., Puckrein, G. A., Araneta, M. R. G., et al. (2015) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2015.06.1328 · Cited by 294 · see citing works
Self-citation
2013 ACCF/AHA Guideline for the Management of Heart Failure: Executive Summary
Yancy, C. W., Jessup, M. L., Bozkurt, B., Butler, J., Casey, D. E., Drazner, M. H., Fonarow, G. C., Geraci, S. A., Horwich, T. B., Januzzi, J. L., et al. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.05.020 · Cited by 290 · see citing works
Self-citation
GLP-1 receptor agonists: a review of head-to-head clinical studies
Trujillo, J. M., Nuffer, W., & Ellis, S. L. (2015) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/2042018814559725 · Cited by 282 · see citing works
2017 ACC Expert Consensus Decision Pathway for Optimization of Heart Failure Treatment: Answers to 10 Pivotal Issues About Heart Failure With Reduced Ejection Fraction
Yancy, C. W., Januzzi, J. L., Allen, L. A., Butler, J., Davis, L. L., Fonarow, G. C., Ibrahim, N. E., Jessup, M. L., Lindenfeld, J., Maddox, T. M., et al. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.11.025 · Cited by 278 · see citing works
Self-citation
Dulaglutide as add-on therapy to SGLT2 inhibitors in patients with inadequately controlled type 2 diabetes (AWARD-10): a 24-week, randomised, double-blind, placebo-controlled trial
Ludvik, B., Frías, J. P., Tinahones, F. J., Wainstein, J., Jiang, H., Robertson, K. E., García-Pérez, L.-E., Woodward, D. B., & Milicevic, Z. (2018) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(18)30023-8 · Cited by 266 · see citing works
Urinary tract and genital infections in patients with type 2 diabetes treated with sodium‐glucose co‐transporter 2 inhibitors: A meta‐analysis of randomized controlled trials
Li, D., Wang, T., Shen, S., Fang, Z., Dong, Y., & Tang, H. (2016) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12825 · Cited by 257 · see citing works
Resurgence in Diabetes-Related Complications
Gregg, E. W., HORA, I. A., & Benoit, S. R. (2019) · JAMA · doi:10.1001/jama.2019.3471 · Cited by 257 · see citing works
Sodium‐Glucose Cotransporter 2 Inhibition for the Prevention of Cardiovascular Events in Patients With Type 2 Diabetes Mellitus: A Systematic Review and Meta‐Analysis
Arnott, C., Li, Q., Kang, A., Neuen, B. L., Bompoint, S., Lam, C. S. P., Rodgers, A., Mahaffey, K. W., Cannon, C. P., Perkovic, V., et al. (2020) · Journal of the American Heart Association · doi:10.1161/jaha.119.014908 · Cited by 247 · see citing works
Effects of empagliflozin on risk for cardiovascular death and heart failure hospitalization across the spectrum of heart failure risk in the EMPA-REG OUTCOME® trial
Fitchett, D., Butler, J., van de Borne, P., Zinman, B., Lachin, J. M., Wanner, C., Woerle, H. J., Hantel, S., George, J. T., Johansen, O. E., et al. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehx511 · Cited by 242 · see citing works
Adjunctive liraglutide treatment in patients with persistent or recurrent type 2 diabetes after metabolic surgery (GRAVITAS): a randomised, double-blind, placebo-controlled trial
Miras, A. D., Pérez-Pevida, B., Aldhwayan, M., Kamocka, A., McGlone, E. R., Al-Najim, W., Chahal, H., Batterham, R. L., McGowan, B., Khan, O., et al. (2019) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(19)30157-3 · Cited by 190 · see citing works
Mortality and Cardiovascular Disease in Type 1 and Type 2 Diabetes
Martínez-Cerón, E., & Rio, F. G. (2017) · New England Journal of Medicine · doi:10.1056/nejmc1706292 · Cited by 171 · see citing works
Cardiovascular Outcomes and Safety of Empagliflozin in Patients With Type 2 Diabetes Mellitus and Peripheral Artery Disease: A Subanalysis of EMPA-REG OUTCOME
Verma, S., Mazer, C. D., Al-Omran, M., Inzucchi, S. E., Fitchett, D., Hehnke, U., George, J. T., & Zinman, B. (2018) · Circulation · doi:10.1161/circulationaha.117.032031 · Cited by 166 · see citing works
Empagliflozin and Assessment of Lower-Limb Amputations in the EMPA-REG OUTCOME Trial
Inzucchi, S. E., Iliev, H., Pfarr, E., & Zinman, B. (2018) · Diabetes Care · doi:10.2337/dc17-1551 · Cited by 162 · see citing works
Cardiac Performance Measure Compliance in Outpatients
Chan, P. S.-F., Oetgen, W. J., Buchanan, D. M., Mitchell, K. R., Fiocchi, F. F., Tang, F., Jones, P. G., Breeding, T., Thrutchley, D., Rumsfeld, J. S., et al. (2010) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2010.03.043 · Cited by 159 · see citing works
Dapagliflozin in patients with type 2 diabetes mellitus: A pooled analysis of safety data from phase IIb/III clinical trials
Jabbour, S. A., Seufert, J., Scheen, A. J., Bailey, C. J., Karup, C., & Langkilde, A. M. (2017) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13124 · Cited by 157 · see citing works
Clinician-Patient Risk Discussion for Atherosclerotic Cardiovascular Disease Prevention
Martin, S. S., Sperling, L. S., Blaha, M. J., Wilson, P. W. F., Gluckman, T. J., Blumenthal, R. S., & Stone, N. J. (2015) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2015.01.043 · Cited by 156 · see citing works
Self-citation
Mediators of the Effects of Canagliflozin on Heart Failure in Patients With Type 2 Diabetes
Li, J., Woodward, M., Perkovic, V., Figtree, G. A., Heerspink, H. J. L., Mahaffey, K. W., de Zeeuw, D., Vercruysse, F., Shaw, W., Matthews, D. R., et al. (2020) · JACC: Heart Failure · doi:10.1016/j.jchf.2019.08.004 · Cited by 144 · see citing works
Interaction between the sodium-glucose-linked transporter 2 inhibitor dapagliflozin and the loop diuretic bumetanide in normal human subjects
Wilcox, C. S., Shen, W., Boulton, D. W., Leslie, B. R., & Griffen, S. C. (2018) · Journal of the American Heart Association · doi:10.1161/jaha.117.007046 · Cited by 139 · see citing works
SGLT2 inhibitors and amputations in the US FDA Adverse Event Reporting System
Fadini, G. P., & Avogaro, A. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30257-7 · Cited by 132 · see citing works
Use of Guideline-Recommended Risk Reduction Strategies Among Patients With Diabetes and Atherosclerotic Cardiovascular Disease: Insights From Getting to an Improved Understanding of Low-Density Lipoprotein Cholesterol and Dyslipidemia Management (GOULD)
Arnold, S. V., de Lemos, J. A., Rosenson, R. S., Ballantyne, C. M., Liu, Y., Mues, K. E., Alam, S., Elliott-Davey, M., Bhatt, D. L., Cannon, C. P., et al. (2019) · Circulation · doi:10.1161/circulationaha.119.041730 · Cited by 130 · see citing works
Self-citation
Comprehensive Cardiovascular Risk Factor Control Improves Survival
Bittner, V., Bertolet, M. H., Barraza, R., Farkouh, M. E., Goldberg, S., Ramanathan, K. B., Redmon, J. B., Sperling, L. S., & Rutter, M. K. (2015) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2015.06.019 · Cited by 129 · see citing works
Self-citation
Utilization of and Adherence to Guideline-Recommended Lipid-Lowering Therapy After Acute Coronary Syndrome
Hirsh, B. J., Smilowitz, N. R., Rosenson, R. S., Fuster, V., & Sperling, L. S. (2015) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2015.05.030 · Cited by 126 · see citing works
Self-citation
Effects of Intensive Glucose Lowering in the Management of Patients With Type 2 Diabetes Mellitus in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Trial
Riddle, M. C. (2010) · Circulation · doi:10.1161/circulationaha.110.960138 · Cited by 107 · see citing works
Professional Practice Committee: Standards of Medical Care in Diabetes—2018
(2018) · Diabetes Care · doi:10.2337/dc18-sppc01 · Cited by 84 · see citing works
The Psychology of Clinical Decision Making — Implications for Medication Use
Avorn, J. (2018) · New England Journal of Medicine · doi:10.1056/nejmp1714987 · Cited by 76 · see citing works
Control of Cardiovascular Risk Factors Among US Adults With Type 2 Diabetes With and Without Cardiovascular Disease
Andary, R., Fan, W., & Wong, N. D. (2019) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2019.05.035 · Cited by 62 · see citing works
DESIGN AND BASELINE CHARACTERISTICS OF THE EVALUATION OF ERTUGLIFOZIN EFFICACY AND SAFETY CARDIOVASCULAR OUTCOMES TRIAL (VERTIS-CV)
Cannon, C. P., McGuire, D. K., Pratley, R. E., et al. (2018) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(18)32366-0 · Cited by 60 · see citing works
Prevalence of Adult-Onset IDDM in the U.S. Population
Harris, M. I., & Robbins, D. C. (1994) · Diabetes Care · doi:10.2337/diacare.17.11.1337 · Cited by 55 · see citing works
Composite cardiovascular risk factor target achievement and its predictors in US adults with diabetes: The Diabetes Collaborative Registry
Fan, W., Song, Y., Inzucchi, S. E., Sperling, L. S., Cannon, C. P., Arnold, S. V., Kosiborod, M., & Wong, N. D. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13625 · Cited by 54 · see citing works
Self-citation
Liraglutide as add-on to sodium-glucose co-transporter-2 inhibitors in patients with inadequately controlled type 2 diabetes: lIRA-ADD2SGLT2i, a 26-week, randomized, double-blind, placebo-controlled trial
Blonde, L., Belousova, L., Fainberg, U., Garcia‐Hernandez, P. A., Jain, S. M., Kaltoft, M. S., Mosenzon, O., Nafach, J., Palle, M. S., & Rea, R. (2020) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13978 · Cited by 54 · see citing works
Cardiovascular Mortality Reduction With Empagliflozin in Patients With Type 2 Diabetes and Cardiovascular Disease
FITCHETT, D. H., Inzucchi, S. E., Lachin, J. M., Wanner, C., van de Borne, P., Mattheus, M., Johansen, O. E., Woerle, H. J., Broedl, U. C., George, J. T., et al. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.11.022 · Cited by 40 · see citing works
Real-world evidence on sodium-glucose cotransporter-2 inhibitor use and risk of Fournier’s gangrene
Yang, J. Y., Wang, T., Pate, V., Buse, J. B., & Stürmer‎, T. (2020) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2019-000985 · Cited by 32 · see citing works
2019 Methodology for Creating Expert Consensus Decision Pathways
Januzzi, J. L., Ahmad, T., Binder, L. G., et al. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.05.035 · Cited by 29 · see citing works
Self-citation
Incretin-Based Therapies: Focus on Effects Beyond Glycemic Control Alone
Davidson, J. A. (2013) · Diabetes Therapy · doi:10.1007/s13300-013-0040-0 · Cited by 15 · see citing works
ASSOCIATION OF PLASMA TRIMETHYLAMINE N-OXIDE LEVEL WITH HEALED CULPRIT PLAQUES EXAMINED BY OPTICAL COHERENCE TOMOGRAPHY IN PATIENTS WITH ST-SEGMENT ELEVATION MYOCARDIAL INFARCTION
Li, J. (2020) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(20)30684-7 · Cited by 14 · see citing works
Professional Practice Committee: Standards of Medical Care in Diabetes—2020
(2019) · Diabetes Care · doi:10.2337/dc20-sppc · Cited by 12 · see citing works
2019 Methodology for Heart House Roundtables
Morris, P. B., Kovacs, R. J., Allen, L. A., Binder, L. G., Birtcher, K. K., Covington, A. M., Gluckman, T. J., & Williams, K. A., Sr. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.05.034 · Cited by 4 · see citing works
Self-citation
Treating T2DM and obesity with bariatric surgery and GLP1 agents
Bailey, C. J. (2019) · Nature Reviews Endocrinology · doi:10.1038/s41574-019-0240-4 · Cited by 2 · see citing works

Flagged first, then by citations

Sorted by citations

2023 AHA/ACC/ACCP/ASPC/NLA/PCNA guideline for the management of patients with chronic coronary disease: a report of the American Heart Association/American College of Cardiology joint committee on clinical practice guidelines
Virani, S. S., Newby, L. K., Arnold, S. V., Bittner, V., Brewer, L. C., Demeter, S. H., Dixon, D. L., Fearon, W. F., Hess, B., Johnson, H. M., et al. (2023) · Circulation · doi:10.1161/cir.0000000000001168 · Cited by 1,598 · see citing works
Comprehensive management of cardiovascular risk factors for adults with type 2 diabetes: a scientific statement from the American Heart Association
Joseph, J. J., Deedwania, P., Acharya, T., Aguilar, D., Bhatt, D. L., Chyun, D. A., Di Palo, K. E., Golden, S. H., Sperling, L. S., & on behalf of the American Heart Association Diabetes Committee of the Council on Lifestyle and Cardiometabolic Health; Council on Arteriosclerosis, T. A. V. B. C. O. C. C. A. C. O. H. (2022) · Circulation · doi:10.1161/cir.0000000000001040 · Cited by 660 · see citing works
Self-citation
2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease
Virani, S. S., Newby, L. K., Arnold, S. V., Bittner, V., Brewer, L. C., Demeter, S. H., Dixon, D. L., Fearon, W. F., Hess, B., Johnson, H. M., et al. (2023) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2023.04.003 · Cited by 596 · see citing works
American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update.
Blonde, L., Umpierrez, G. E., Reddy, S. S., McGill, J. B., Berga, S. L., Bush, M., Chandrasekaran, S., DeFronzo, R. A., Einhorn, D., Galindo, R. J., et al. (2022) · Endocrine Practice · doi:10.1016/j.eprac.2022.08.002 · Cited by 507 · see citing works
Self-citation
10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2023
ElSayed, N. A., Aleppo, G., Aroda, V. R., Bannuru, R. R., Brown, F. M., Bruemmer, D., Collins, B. S., Das, S. R., Hilliard, M. E., Isaacs, D., et al. (2023) · Diabetes Care · doi:10.2337/dc23-s010 · Cited by 465 · see citing works
Self-citation
American Association of Clinical Endocrinology consensus statement: comprehensive type 2 diabetes management algorithm—2023 update
Samson, S. L., Vellanki, P., Blonde, L., Christofides, E. A., Galindo, R. J., Hirsch, I. B., Isaacs, S. D., Izuora, K. E., Low Wang, C. C., Twining, C. L., et al. (2023) · Endocrine Practice · doi:10.1016/j.eprac.2023.02.001 · Cited by 375 · see citing works
Association of race/ethnicity, gender, and socioeconomic status with sodium-glucose cotransporter 2 inhibitor use among patients with diabetes in the US
Eberly, L. A., Yang, L., Eneanya, N. D., Essien, U., Julien, H., Nathan, A. S., Khatana, S. A. M., Dayoub, E. J., Fanaroff, A. C., Giri, J., et al. (2021) · JAMA Network Open · doi:10.1001/jamanetworkopen.2021.6139 · Cited by 350 · see citing works
10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025
American Diabetes Association Professional Practice Committee, ElSayed, N. A., McCoy, R. G., Aleppo, G., Balapattabi, K., Beverly, E. A., Briggs Early, K., Bruemmer, D., Das, S. R., Echouffo-Tcheugui, J. B., et al. (2025) · Diabetes Care · doi:10.2337/dc25-s010 · Cited by 339 · see citing works
Self-citation
2024 ACC Expert Consensus Decision Pathway for Treatment of Heart Failure With Reduced Ejection Fraction
Maddox, T. M., Januzzi, J. L., Allen, L. A., Breathett, K., Brouse, S., Butler, J., Davis, L. L., Fonarow, G. C., Ibrahim, N. E., Lindenfeld, J., et al. (2024) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2023.12.024 · Cited by 362 · see citing works
Self-citation
Racial, Ethnic, and Socioeconomic Inequities in Glucagon-Like Peptide-1 Receptor Agonist Use Among Patients With Diabetes in the US
Eberly, L. A., Yang, L., Essien, U. R., Eneanya, N. D., Julien, H. M., Luo, J., Nathan, A. S., Khatana, S. A. M., Dayoub, E. J., Fanaroff, A. C., et al. (2021) · JAMA Health Forum · doi:10.1001/jamahealthforum.2021.4182 · Cited by 288 · see citing works
Comparative efficacy of glucose-lowering medications on body weight and blood pressure in patients with type 2 diabetes: a systematic review and network meta-analysis
Tsapas, A., Karagiannis, T., Kakotrichi, P., Avgerinos, I., Mantsiou, C., Tousinas, G., Manolopoulos, A., Liakos, A., Malandris, K., Matthews, D. R., et al. (2021) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14451 · Cited by 179 · see citing works
National Trends in Use of Sodium‐Glucose Cotransporter‐2 Inhibitors and Glucagon‐like Peptide‐1 Receptor Agonists by Cardiologists and Other Specialties, 2015 to 2020
Adhikari, R., Jha, K., Dardari, Z., Heyward, J., Blumenthal, R. S., Eckel, R. H., Alexander, G. C., & Blaha, M. J. (2022) · Journal of the American Heart Association · doi:10.1161/jaha.121.023811 · Cited by 166 · see citing works
Glucagon-Like Peptide 1 Receptor Agonists and Heart Failure: The Need for Further Evidence Generation and Practice Guidelines Optimization
Khan, M. S., Fonarow, G. C., McGuire, D. K., Hernandez, A. F., Vaduganathan, M., Rosenstock, J., Handelsman, Y., Verma, S., Anker, S. D., McMurray, J. J. V., et al. (2020) · Circulation · doi:10.1161/circulationaha.120.045888 · Cited by 139 · see citing works
Self-citation
Utilization Rates of SGLT2 Inhibitors and GLP-1 Receptor Agonists and Their Facility-Level Variation Among Patients With Atherosclerotic Cardiovascular Disease and Type 2 Diabetes: Insights From the Department of Veterans Affairs
Mahtta, D., Ramsey, D. J., Lee, M. T., Chen, L., Al Rifai, M., Akeroyd, J. M., Vaughan, E. M., Matheny, M. E., Santo, K. R. D. E., Navaneethan, S. D., et al. (2022) · Diabetes Care · doi:10.2337/dc21-1815 · Cited by 137 · see citing works
Glucagon-like peptide-1 receptor agonists in diabetic kidney disease: a review of their kidney and heart protection
Michos, E. D., Bakris, G. L., Rodbard, H. W., & Tuttle, K. R. (2023) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2023.100502 · Cited by 125 · see citing works
Guidelines for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes
Kelsey, M. D., Nelson, A. J., Green, J. B., Granger, C. B., Peterson, E. D., McGuire, D. K., & Pagidipati, N. J. (2022) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2022.02.046 · Cited by 106 · see citing works
Sodium-glucose cotransporter-2 inhibitors versus glucagon-like peptide-1 receptor agonists and the risk for cardiovascular outcomes in routine care patients with diabetes across categories of cardiovascular disease
Patorno, E., Htoo, P. T., Glynn, R. J., Schneeweiss, S., Wexler, D. J., Pawar, A., Bessette, L. G., Chin, K., Everett, B. M., & Kim, S. C. (2021) · Annals of Internal Medicine · doi:10.7326/m21-0893 · Cited by 103 · see citing works
Self-citation
Glucose-Lowering Drugs to Reduce Cardiovascular Risk in Type 2 Diabetes
Kalyani, R. R. (2021) · New England Journal of Medicine · doi:10.1056/nejmcp2000280 · Cited by 101 · see citing works
Self-citation
Benefits of GLP-1 (Glucagon-Like Peptide 1) Receptor Agonists for Stroke Reduction in Type 2 Diabetes: A Call to Action for Neurologists
Goldenberg, R. M., Cheng, A. Y. Y., Fitzpatrick, T., Gilbert, J. D., Verma, S., & Hopyan, J. J. (2022) · Stroke · doi:10.1161/strokeaha.121.038151 · Cited by 82 · see citing works
Use of Lipid-, Blood Pressure–, and Glucose-Lowering Pharmacotherapy in Patients With Type 2 Diabetes and Atherosclerotic Cardiovascular Disease
Nelson, A. J., O’Brien, E. C., Kaltenbach, L. A., Green, J. B., Lopes, R. D., Morse, C. G., Al-Khalidi, H. R., Aroda, V. R., Cavender, M. A., Gaynor, T., et al. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2021.48030 · Cited by 78 · see citing works
Self-citation
Contemporary National Patterns of Eligibility and Use of Novel Cardioprotective Antihyperglycemic Agents in Type 2 Diabetes Mellitus
Nargesi, A. A., Jeyashanmugaraja, G. P., Desai, N., Lipska, K., Krumholz, H., & Khera, R. (2021) · Journal of the American Heart Association · doi:10.1161/jaha.121.021084 · Cited by 61 · see citing works
The effect of <scp>GLP</scp> ‐1 receptor agonists on circulating inflammatory markers in type 2 diabetes patients: A systematic review and meta‐analysis
Ren, Y., Chen, Y., Zheng, W., Kong, W., Liao, Y., Zhang, J., Wang, M., & Zeng, T. (2025) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.16366 · Cited by 59 · see citing works
Second-Line Therapy for Type 2 Diabetes Management: The Treatment/Benefit Paradox of Cardiovascular and Kidney Comorbidities
McCoy, R. G., Van Houten, H. K., Karaca-Mandic, P., Ross, J. S., Montori, V. M., & Shah, N. D. (2021) · Diabetes Care · doi:10.2337/dc20-2977 · Cited by 57 · see citing works
Diabetes and Progression of Heart Failure
Echouffo-Tcheugui, J. B., Ndumele, C. E., Zhang, S., Florido, R., Matsushita, K., Coresh, J., Skali, H., Shah, A. M., & Selvin, E. (2022) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2022.03.378 · Cited by 54 · see citing works
Preoperative SGLT2 inhibitor use and postoperative diabetic ketoacidosis
Dixit, A. A., Bateman, B. T., Hawn, M. T., Odden, M. C., & Sun, E. C. (2025) · JAMA Surgery · doi:10.1001/jamasurg.2024.7082 · Cited by 47 · see citing works
Effects of glucagon‐like peptide‐1 receptor agonists on cardiovascular and renal outcomes: A <scp>meta‐analysis</scp> and <scp>meta‐regression</scp> analysis
Yoshiji, S., Minamino, H., Tanaka, D., Yamane, S., Harada, N., & Inagaki, N. (2022) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14666 · Cited by 40 · see citing works
Re‐examining the widespread policy of stopping sodium‐glucose cotransporter‐2 inhibitors during acute illness: A perspective based on the updated evidence
Khunti, K., Aroda, V. R., Bhatt, D. L., Bozkurt, B., Buse, J. B., Heerspink, H. L., Inzucchi, S. E., Lam, C. S. P., Marx, N., McMurray, J. J. V., et al. (2022) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14805 · Cited by 37 · see citing works
Self-citation
Efficacy and Safety of Semaglutide for the Management of Obese Patients With Type 2 Diabetes and Chronic Heart Failure in Real-World Clinical Practice
Pérez-Belmonte, L. M., Sanz-Cánovas, J., García de Lucas, M. D., Ricci, M., Avilés-Bueno, B., Cobos-Palacios, L., Pérez-Velasco, M. A., López-Sampalo, A., Bernal-López, M. R., Jansen-Chaparro, S., et al. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.851035 · Cited by 35 · see citing works
Race and ethnicity and pharmacy dispensing of SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetes
Rodriguez, L. A., Finertie, H., Neugebauer, R. S., Gosiker, B., Thomas, T. W., Karter, A. J., Gilliam, L. K., Oshiro, C., An, J., Simonson, G., et al. (2024) · The Lancet Regional Health - Americas · doi:10.1016/j.lana.2024.100759 · Cited by 31 · see citing works
Lifestyle Medicine for Obesity in the Era of Highly Effective Anti-Obesity Treatment
Sannidhi, D., Abeles, R., Andrew, W., Bonnet, J. P., Vitale, K., Niranjan, V., Gulati, M., Pauly, K., Moran, R., Alexander, L., et al. (2025) · Nutrients · doi:10.3390/nu17142382 · Cited by 29 · see citing works
Examining the evidence for weight management in individuals with type 2 diabetes
Garvey, W. T., Umpierrez, G. E., Dunn, J. P., Kwan, A. Y. M., Varnado, O. J., Konig, M., & Levine, J. A. (2022) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14764 · Cited by 18 · see citing works
Comparative efficacy and tolerability of currently approved incretin mimetics: A systematic analysis of placebo‐controlled clinical trials
Kang, Y. M., Punov, V., Lim, S., & Nauck, M. A. (2025) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.16398 · Cited by 20 · see citing works
Effects of once‐weekly subcutaneous semaglutide on coronary artery disease outcomes in patients with type 2 diabetes with or at high risk for cardiovascular disease: Insights from the SUSTAIN‐6 trial
Kolkailah, A. A., Lingvay, I., Dobrecky‐Mery, I., Aharonovich, A., David, J., Holse, C., Rasmussen, S., & McGuire, D. K. (2023) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14941 · Cited by 6 · see citing works
Evidence-based SGLT2 inhibitor and GLP-1 receptor agonist use by race in the VA healthcare system
Bolden, D. M., Richardson, V., Salahuddin, T., Henderson, K., Hess, P. L., Raghavan, S., Saxon, D. R., Ho, P. M., Waldo, S. W., & Schwartz, G. G. (2025) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2025.100966 · Cited by 4 · see citing works

Authors: Das, S. R., Everett, B. M., Birtcher, K. K., Brown, J. M., Januzzi, J. L., Kalyani, R. R., Kosiborod, M., Magwire, M., Morris, P. B., Neumiller, J. J., & Sperling, L. S.
ORCID: Das, Sandeep R.
Everett, Brendan M.
Birtcher, Kim K.
Brown, Jenifer M.
Januzzi, James L.
Kalyani, Rita R.
Kosiborod, Mikhail
Magwire, Melissa
Neumiller, Joshua J.
Sperling, Laurence S.
Venue: Journal of the American College of Cardiology
Publisher: Elsevier BV
Published: 2020-09
Volume: 76
Issue: 9
Pages: 1117-1145
ISSN: 0735-1097 (ISSN-L)
DOI: 10.1016/j.jacc.2020.05.037
PMC: PMC7545583
OpenAlex: W3047536039
Semantic Scholar: 6f3c96e39518ec999a6b97287d2a6d166e67b51b
Cited by: 466
References: 111
Citations by year: 2026: 41 · 2025: 75 · 2024: 52 · 2023: 67 · 2022: 117 · 2021: 104 · 2020: 10
FWCI: 56.38
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/legal/tdmrep-license (tdm)
www.elsevier.com/open-access/userlicense/1.0/ (vor, 365 d)
Locations: Journal of the American College of Cardiology (publishedVersion)
PubMed (publishedVersion)
PubMed Central (acceptedVersion)
Funders: National Heart, Lung, and Blood Institute (T32HL007604)
Topics: Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Antiplatelet Therapy and Cardiovascular Diseases
Keywords: type 2 diabetes, cardiovascular risk reduction, new drugs, cardiovascular disease prevention, expert consensus, decision pathways, SGLT2 inhibitors, GLP-1 receptor agonists
MeSH terms: Clinical Decision-Making, Heart Disease Risk Factors, Cardiology, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Humans, United States, Committee Membership, Consensus, Risk Reduction Behavior, Research Report

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

2020 Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes

Abstract

Integrity signals

Claims the paper makes

Claims other papers make about this one

Self-check

Cites

Cited by

Related

Record

About these checks